CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at $9.56 ($81,262)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at $9.57 ($81,310)
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at $10.85 ($92,205)
- 144 Insider Sale of Securities
- 4 Open-market buy Chief Financial Officer bought 10,000 shares at an average $10.10 ($100,988)
- 4 Open-market buy Director bought 6,000 shares at $10.21 ($61,250)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Grant or award Chief Operating Officer acquired 13,987 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 8-K Event Regulation FD disclosure · Other events
- SCHEDULE 13G Stake Statement of Beneficial Ownership
Page 9 of 13 · 253 filings